This approach demonstrates that coexpressing CD19/CD20/CD22 CAR T-cell is regarded as an excellent solution for treatment in ALL, due to simultaneous targeting of CD19, CD20, and CD22. Here, CD19 is linked to acute lymphoblastic leukemia.